MoonLake Immunotherapeutics (MLTX) presents a promising biotech opportunity with its lead asset, sonelokimab, showing strong Phase 2 efficacy in HS and PsA. With $480M in cash and a $500M credit facility, MLTX has no near-term funding needs. Phase 3 data expected in September 2025 could lead to substantial upside, with peak HS sales estimates of $1.5–2.0B. MLTX offers a compelling risk/reward profile. While not among the 30 Most Popular Stocks Among Hedge Funds, 38 hedge fund portfolios held MLTX at the end of the first quarter.

Bio-Techne Corporation (TECH) has seen a 10% stock price increase, driven by organic growth and instrument sales rebounding. MoonLake’s focused, binary biotech catalyst presents an exciting opportunity.

Read more at Yahoo Finance: MoonLake Immunotherapeutics (MLTX): A Bull Case Theory